Latest Regulatory Approval News

New Zealand Rural Land Company’s 75%-owned partnership has conditionally agreed to sell five Hawke’s Bay orchards for $18.84 million, as uncertainty from the Kiwi Crunch administration continues to cloud FY26 earnings. Completion depends on Overseas Investment Office consent.

High-Tech Metals will ask shareholders to approve a new identity, Beyond Discovery Limited, alongside a proposed ASX code change from HTM to BYD. The move signals a shift toward developing its Mt Fisher and Mt Eureka gold projects, but changes no assets, operations or capital structure.

Pioneer Minerals has entered a voluntary suspension while it prepares an announcement covering a capital raise and material acquisition. Trading is expected to resume on 9 October 2026 or once the announcement is released, whichever comes first.

Gold Fields’ proposed acquisition of BHP’s Kambalda Nickel Concentrator could give Lunnon Metals a new processing angle for its nearby Foster-Baker nickel assets. The opportunity remains exploratory, with completion not expected until 2027 and no commercial arrangement disclosed.

Kalamazoo Resources has secured A$10 million from a Saudi-led strategic investor and existing shareholder YT International at a 29% premium to its last close. The funding gives the Ashburton Gold Project more room to advance drilling, feasibility work and the Xanadu prospect evaluation.

Ovanti has reported a A$23.61 million FY2026 loss, A$21.27 million in operating cash outflows and only A$291,867 in cash at year end. The ASX-listed fintech has abandoned BNPL globally, but says its continuing operations and proposed funding initiatives provide a basis to keep trading despite a material going-concern uncertainty.

Yugo Metals has secured six-year access to the private land covering its planned Petrovo drill sites in Bosnia and Herzegovina, paying EUR300,000 and issuing 18 million escrowed shares. An IP survey is due to begin next week, with drilling planned for the fourth quarter subject to approvals.

Astral Resources will issue Estrella Resources 20 million shares valued at $3 million to acquire nickel rights across five tenements within the broader Mandilla development footprint. Completion is targeted for 12 October, but remains conditional on shareholder, regulatory and third-party approvals.

Estrella Resources has agreed to divest its nickel rights across five Western Australian tenements for 20 million Astral Resources shares valued at $3 million. The deal remains conditional, but would sharpen Estrella’s focus on its Timor-Leste exploration portfolio while preserving exposure to Astral’s equity upside.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Famien Resources will sell its West Yilgarn exploration portfolio to Voltaic Strategic Resources for $330,000 upfront, with a further $2 million tied to future gold resource milestones. The deal gives Famien immediate cash while leaving the larger deferred payment dependent on exploration success by the buyer.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.